UB Paderborn / Katalog / Suche / in CDI

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

Clinical cancer research, 2009-06, Vol.15 (12), p.3912-3916

2009

Volltextzugriff (PDF)

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Nature medicine, 2018-02, Vol.24 (2), p.186-193

2018

Volltextzugriff (PDF)

Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8), p.3042-3051

2011

Volltextzugriff (PDF)

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy

Genes & cancer, 2010-07, Vol.1 (7), p.708-716

2010

Volltextzugriff (PDF)

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

Biochemical journal, 2010-09, Vol.430 (3), p.461-476

2010

Volltextzugriff (PDF)

Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry

Cell biochemistry and biophysics, 2013-09, Vol.67 (1), p.139-147

2013

Volltextzugriff (PDF)

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor

Nature chemical biology, 2017-11, Vol.13 (11), p.1164

2017

Volltextzugriff (PDF)

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

Journal of medicinal chemistry, 2021-03, Vol.64 (5), p.2501-2520

2021

Volltextzugriff (PDF)

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Blood, 2010-09, Vol.116 (9), p.1515-1523

2010

Volltextzugriff (PDF)

Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1147-1147

2017

Volltextzugriff (PDF)

Assays for proteasome inhibition

Methods in molecular medicine, 2003, Vol.85, p.163

2003

Volltextzugriff (PDF)

Inhibition of NEDDB-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

Cancer research (Chicago, Ill.), 2011, Vol.71 (8), p.3042-3051

2011

Volltextzugriff (PDF)

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S [beta]5-subunit

Biochemical journal, 2012-04, Vol.430 (9, 2010)

2012

Volltextzugriff (PDF)

MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells

Blood, 2008-11, Vol.112 (11), p.3621-3621

2008

Volltextzugriff (PDF)

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma

Blood, 2010-09, Vol.116 (9), p.1515-1523

2010

Volltextzugriff (PDF)

MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Blood, 2008-11, Vol.112 (11), p.606-606

2008

Volltextzugriff (PDF)

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit

Biochemical journal, 2010-09, Vol.430 (3), p.461-476

2010

Volltextzugriff (PDF)

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

Alzheimer's & dementia, 2020-08, Vol.16 (8), p.1182-1195

2020

Volltextzugriff (PDF)

A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-Lactone

Journal of the American Chemical Society, 1999-11, Vol.121 (43), p.9967-9976

1999

Volltextzugriff (PDF)

A longitudinal program for biomarker development in Parkinson's disease: A feasibility study

Movement disorders, 2009-10, Vol.24 (14), p.2081-2090

2009

Volltextzugriff (PDF)

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts

Movement disorders, 2011-03, Vol.26 (4), p.608-613

2011

Volltextzugriff (PDF)

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts

Movement disorders, 2009-12, Vol.24 (16), p.2370-2378

2009

Volltextzugriff (PDF)

Common alleles at 6q25.1 and 1 p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

Human molecular genetics, 2011, Vol.20 (16), p.3304-3321

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

Assays for proteasome inhibition

Inhibition of NEDDB-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S [beta]5-subunit

MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma

MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

A Novel and Efficient Synthesis of a Highly Active Analogue of clasto-Lactacystin β-Lactone

A longitudinal program for biomarker development in Parkinson's disease: A feasibility study

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts

Common alleles at 6q25.1 and 1 p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

Suchergebnisse filtern